Tables and box

TABLES

1.1 Share of GDP allocated to health in the G-7 countries 18
1.2 Per capita health expenditures in the G-7 countries 19
1.3 Health services employment and share of total employment in the G-7 countries, selected years 20
1.4 Employment in selected sectors in the G-7 countries, 1996 20
1.5 Selected health service inputs and capabilities among the G-7 countries, 2000 23
1.6 Public share of health expenditures among the G-7 countries 23
1.7 Proportion of national health expenditures spent on selected health care providers: inpatient hospital services and ambulatory physician services in the G-7 countries 27
1.8 Proportion of spending on pharmaceuticals in the total health expenditures in G-7 countries 31
1.9 Spending on pharmaceutical R&D in selected countries, 1998 32
1.10 Projected proportion of older people in the total population, 1996–2050 34
4.1 Antidepressants: factors determining 1997 prices paid by HMOs and pharmacies 88
4.2 Calcium channel blockers: factors determining 1997 prices paid by HMOs and pharmacies 90
4.3 Antimicrobials: factors determining 1997 prices paid by HMOs and pharmacies 92
4.4 Antihistamines: factors determining 1997 prices paid by HMOs and pharmacies 94
4.5 Glaucoma ophthalmic solutions: factors determining 1997 prices paid by HMOs and pharmacies 96
5.1 Share of total business enterprise funds and government funds in the university R&D sector 115
5.2 University of Ferrara, share of business enterprise funds and government funds in the university R&D areas 121
6.1 A taxonomy of the determinants of a firm’s value 133
6.2 Biotech companies: Europe versus USA 137
Tables and box

6.3 Patent applications at the European Patent Office 137
6.4 Activity in genetic engineering, by type of institution 138
6.5 The changing structure of company costs in the pharmaceutical industry, 1973–89 139
6A.1 Lev’s estimation of knowledge capital 147
6A.2 Top ranking companies in the health industry 148
7.1 The ‘ladder of success’ for NHS hospitals 156
7.2 Key national reference cost statistics 157
8.1 Capital stock and capital–output ratio in the USA, 1929–90 173
8.2 Knowledge capital estimations for selected companies, 30 Sept. 2000 177
8.3 Knowledge capital estimations, comparisons among industries, 30 Sept. 2000 179
8.4 R&D indicators for pharmaceutical and biotech companies 181
8.5 The changing structure of company costs in the pharmaceutical industry, 1973–89 181
9.1 Results of the Poisson regressions predicting the likelihood of a biotech firm in a zip code 214
9.2 Variance–covariance matrix 215
9.3 Distance between simulated and actual firms 215
10.1 Economic impact of UC San Diego’s corporate research support (and royalties plus fees) in 1998 227
10.2 Economic impact of University of California’s corporate research support (and royalties plus fees) in 1998 228
10.3 Economic impact of California’s research universities’ corporate research support (and royalties plus fees) in 1998 229
11.1 HIBs by regions, provinces and local systems 239
11.2 Types of local systems involved by the presence of HIBs 241
11.3 Headquarters and manufacturing plants belonging to HIBs, by types of local systems 242
11.4 Local systems belonging to 1LS, by types, with pharmaceutical and/or biomedical specialization indexes higher than 2.0 242
12.1 Comparison between biotechnology industries in 2002 262
12.2 Development of biotechnologies in Europe: comparative analysis, 2001 262
12.3 The burden of taxation in France 263
12.4 Financial aspects, 2000 269
12.5 Total investment in the Genopole cluster, 2000 269

BOX

11.1 Sources, legends and terminology 257